Genelux (GNLX) Income from Continuing Operations (2022 - 2026)
Genelux (GNLX) recorded quarterly Income from Continuing Operations of 8998000.0 in Q1 2026, up 3.08% quarter-over-quarter from 9284000.0 in Q4 2025, and down 17.9% on a YoY basis from 10959581.23 in Q1 2025.
Genelux (GNLX) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Genelux's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 8998000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 17.9% year-over-year to 8998000.0; the TTM figure through Mar 2026 stood at 33869000.0 (down 10.59% YoY), while the FY2025 annual figure was 32503000.0, down 4.86% from the prior year.
- Income from Continuing Operations was 8998000.0 for Q1 2026 at Genelux, up from 9284000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4909000.0 in Q3 2022 to a low of 9572000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 6535666.67 across 5 years, with a median of 7568000.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 208.88% in 2023, then increased 17.99% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 3495000.0 in 2022, then tumbled by 93.62% to 6767000.0 in 2023, then tumbled by 41.08% to 9547000.0 in 2024, then increased by 2.75% to 9284000.0 in 2025, then gained by 3.08% to 8998000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 8998000.0 (Q1 2026), 9284000.0 (Q4 2025), and 8019000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.00 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Sep 30, 2025 | -8.02 Mn |
| Jun 30, 2025 | -7.57 Mn |
| Mar 31, 2025 | -7.63 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Sep 30, 2024 | -6.72 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | -7.85 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -5.42 Mn |
| Mar 31, 2023 | -9.57 Mn |
| Dec 31, 2022 | -3.50 Mn |
| Sep 30, 2022 | 4.91 Mn |